Pricing: Observations Nazeem Mohamed Chairman, Uganda Pharmaceutical Manufacturers Association (UPMA) C.E.O. Kampala Pharmaceutical Industries (1996) Ltd
Pricing: Information/Data Gathering Robust methodologies and publications exist (WHO/HAI) on pricing of medicines Share data across countries on “public procurement” as means to increase efficiency Data must be shared across multi-sectors before policies are finalised – Transparency is the key!! Pricing/Affordability must go hand in hand Convert prices into a Availability Index (no’s days wages to pay for treatment) A finding may have many causes!! Information must be dynamic and communicated!!!
Pricing: Policy • Pricing is only one aspect of the “access” issue and there is NO one answer!! • Effective policy will have to be a package of measures addressing pricing, e.g. • Generic substitution • Price/margin controls • Procurement efficiency • Differential pricing • Support local manufacturing • Increase public sector availability • Need for a financing mechanism for the poor and even the near poor • Must measure the impact of policy and be prepared to adjust as necessary
Pricing: Issues • Watch for unwanted negative effects • Price controls may impact on availability • Growth of cheaper sub standard products • Asymmetric information, i.e. Choice of medicine not made by the end consumer!! • Consider the impact of “Chronic diseases” when developing policy (priorities!) • Health system strengthening • Financing options
Thank you Nazeem Mohamed Email: firstname.lastname@example.org